Month: February 2020

WARREN, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced positive top-line data from a recently completed acute, intra-patient, dose escalation, hemodynamics study (PHPF-002) of INOpulse® for the treatment of Pulmonary Hypertension associated with Pulmonary Fibrosis (PH-PF).The top-line results from PHPF-002 demonstrated that acute treatment with INOpulse provided statistically and clinically significant improvements in hemodynamic parameters, including:Pulmonary vascular resistance reduced by 21%, with increased benefit (p

TULSA, OK, Feb. 18, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — RJD Green (OTCPK: RJDG), Silex Holdings announced three commercial projects were sold in January 2020.RJD Green Inc. announced the awarding of three commercial projects to Silex Holdings specialty construction division. The contracts total $238,351, making a positive start on increased commercial division revenues in 2020.Silex Holdings is continuing its commercial business growth as a primary focus in 2020.Ron Brewer, CEO of RJD Green Inc., states, “Silex continues the progression in solidifying long-term relationships with valued clients in the construction industry by providing custom quality product with fast turnaround times on our clients’ orders. With an increased commercial business development program implemented, Silex will cautiously continue the broadening...

Dublin, California, Feb. 18, 2020 (GLOBE NEWSWIRE) —Connie Kao 925-965-4668 connie.kao@ros.com

LONDON, Feb. 18, 2020 (GLOBE NEWSWIRE) — Ferroglobe PLC (NASDAQ:GSM) announced today that it will issue fourth quarter and full year 2019 financial results after the close of the market on Monday, March 2, 2020 and will host the quarterly earnings call on Tuesday, March 3, 2020.  Ferroglobe invites all interested persons to participate on its conference call at 9:00 AM, Eastern Time. The dial-in number for the call for participants in the United States is +1-877-293-5491 (conference ID 4987662). International callers should dial +1-914-495-8526 (conference ID 4987662). Please dial in at least five minutes prior to the call to register. The call may also be accessed via an audio webcast available at https://edge.media-server.com/mmc/p/ci6ip3a5Date: March 3, 2020Time: 9:00 AM ESTListen via Internet: https://edge.media-server.com/mmc/p/ci6ip3a5United...

HOUSTON, Feb. 18, 2020 (GLOBE NEWSWIRE) — Cardtronics, the world’s largest ATM operator, today announced that Amazon customers can now complete Amazon Cash transactions at more than 400 cash-accepting Cardtronics ATMs in the U.S. The ATMs, part of the Allpoint+ Network of surcharge-free deposit-taking ATMs for Allpoint members, operate card-free, allowing Amazon customers to add cash to their Amazon Balance to make future purchases on Amazon’s online store using only the phone number linked to their Amazon account with no added fees.Customers start by verifying their mobile phone number and identifying a participating Allpoint+ ATM location at amazon.com/amazoncash. Once at a participating location, the customer can add cash in any amount between $5 and $500 to their Amazon Balance by simply entering their mobile phone number; no...

Folsom, Feb. 18, 2020 (GLOBE NEWSWIRE) —                                                                                                 Media Contact:  Marissa Travaline(609) 561-9000 ext. 4227mtravaline@sjindustries.com                                                                                                          Investor Contact: Dan Fidell(609) 561-9000 ext. 7027dfidell@sjindustries.comFOR IMMEDIATE RELEASESJI Declares Quarterly DividendFOLSOM, NJ, February 18, 2020 – SJI’s (NYSE: SJI) board of directors declared its regular dividend of $0.29500 per share for the first quarter of 2020. The dividend is payable April 2, 2020 to shareholders of record at the close of business March 18, 2020. This is SJI’s 69th consecutive year of paying dividends, reflecting the company’s commitment to a consistent, sustainable dividend.About...

TORONTO, Feb. 18, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”), a company focused on the research, development and commercialization of novel cannabinoid-based and life sciences products, is pleased to provide an update on the Company’s clinical development plan for Cannabidiol (“CBD”) in the treatment of Autoimmune Hepatitis (AIH).Revive is currently in the process of preparing its Investigational New Drug (“IND”) application for submission to the U.S. Food and Drug Administration (“FDA”) for CBD in the treatment of AIH.  The Company plans to submit the IND within ninety days with the objective to proceed with a proposed Phase 1/2a clinical study to determine the recommended dose of CBD for future clinical studies of AIH, to assess its safety, efficacy and clinical benefit, as well as to support...

PHOENIX, AZ, Feb. 18, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — No Borders, Inc. (OTC: NBDR), announced today that actor and WWE Hall of Fame Wrestler Kevin Nash has joined its subsidiary No Borders Naturals® as a Global Brand Ambassador and Company Spokesperson to help spread awareness about the benefits that hemp cannabidiol (CBD) provides for athletes and active consumers. “Kevin is exactly the type of person that we are looking to partner with on our No Borders Naturals journey,” said No Borders Naturals CEO Joseph Snyder. “He not only has the values and family centric ideals that we hold dear but he has spent a vibrant life taking (quite literally) a beating and coming out on top smiling!”Kevin Scott Nash is a retired Detroit-born American actor and former professional wrestler, best known for his tenures...

The Company has finalized the formulation blueprint for its proposed Pharmaceutical Grade Version of Tauri-Gum™NEW YORK, NY, Feb. 18, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today reported meaningful progress in the development of its pharmaceutical grade version of Tauri-Gum™.  On January 13, 2020, the Company announced the formation of a wholly owned subsidiary, “Tauriga Pharma Corporation,” to reflect the ongoing development of a pharmaceutical Nausea Regulation (“Anti-Nausea”) product.  The Company has finalized the formulation for this proposed...